XHKG6078
Market cap1.15bUSD
Dec 27, Last price
14.32HKD
1D
-1.51%
1Q
-30.65%
IPO
-46.37%
Name
Hygeia Healthcare Holdings Co Ltd
Chart & Performance
P/E
12.32
P/S
2.06
EPS
1.09
Div Yield, %
1.05%
Shrs. gr., 5y
1.02%
Rev. gr., 5y
39.70%
Revenues
4.08b
+27.57%
Net income
683m
+43.24%
CFO
783m
+14.22%
Dividend
Jun 30, 20230.1636 HKD/sh
Profile
Hygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 4,076,680 27.57% | 3,195,648 38.02% | 2,315,349 65.17% | ||||
Cost of revenue | 3,253,178 | 2,471,534 | 1,796,116 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 823,502 | 724,114 | 519,233 | ||||
NOPBT Margin | 20.20% | 22.66% | 22.43% | ||||
Operating Taxes | 171,139 | 161,435 | 119,642 | ||||
Tax Rate | 20.78% | 22.29% | 23.04% | ||||
NOPAT | 652,363 | 562,679 | 399,591 | ||||
Net income | 682,928 43.24% | 476,784 8.00% | 441,457 159.55% | ||||
Dividends | (94,479) | (74,081) | |||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 681,740 | (35,828) | |||||
BB yield | |||||||
| Debt | |||||||
Debt current | 403,158 | 183,130 | 34,765 | ||||
Long-term debt | 2,324,659 | 1,108,715 | 1,197,286 | ||||
Deferred revenue | 34,573 | 34,431 | |||||
Other long-term liabilities | 214,113 | (161,555) | (149,681) | ||||
Net debt | 1,959,820 | (4,944,448) | (4,752,922) | ||||
| Cash flow | |||||||
Cash from operating activities | 782,840 | 685,378 | 426,251 | ||||
CAPEX | (925,678) | (593,121) | (663,092) | ||||
Cash from investing activities | (2,863,474) | (372,060) | (850,846) | ||||
Cash from financing activities | 1,775,256 | (154,206) | 754,495 | ||||
FCF | (1,065,187) | 221,976 | 1,312,398 | ||||
| Balance | |||||||
Cash | 767,997 | 884,714 | 1,104,469 | ||||
Long term investments | 5,351,579 | 4,880,504 | |||||
Excess cash | 564,163 | 6,076,511 | 5,869,206 | ||||
Stockholders' equity | 1,425,758 | 744,921 | 324,441 | ||||
Invested Capital | 8,629,411 | 5,424,061 | 5,361,688 | ||||
ROIC | 9.28% | 10.43% | 8.21% | ||||
ROCE | 8.96% | 11.50% | 8.95% | ||||
| EV | |||||||
Common stock shares outstanding | 631,119 | 616,821 | 618,000 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | 1,034,044 | 871,165 | 629,306 | ||||
EV/EBITDA | |||||||
Interest | 43,170 | 40,828 | 23,085 | ||||
Interest/NOPBT | 5.24% | 5.64% | 4.45% | ||||